Bimekizumab response maintenance through two years of treatment in patients with moderate to severe plaque psoriasis who responded after 16 weeks: Interim results from the BE BRIGHT open-label extension trial

Main Article Content

Bruce Strober
Akihiko Asahina
Ulrich Mrowietz
Mark Lebwohl
Peter Foley
Richard Langley
Jonathan Barker
Christopher Cioffi
Nancy Cross
Maggie Wang
Carle Paul

Keywords

bimekizumab, psoriasis, BE BRIGHT, open label extension trial

Abstract

N/A

References

1. Adams R et al. Front Immunol 2020;11:1894;

2. Reich K et al. Lancet 2021;397:487–98; 3Gordon K et al. Lancet 2021;397:475–86; 4Warren R et al. NEJM 2021; DOI: 10.1056/NEJMoa2102388; 5Reich K et al. NEJM 2021; DOI: 10.1056/NEJMoa2102383

Most read articles by the same author(s)

<< < 3 4 5 6 7 8 9 > >>